These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29486103)

  • 1. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
    Pratt J; Crispin P
    Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
    Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays.
    Hillarp A; Strandberg K; Gustafsson KM; Lindahl TL
    J Thromb Haemost; 2020 Aug; 18(8):1866-1873. PubMed ID: 32294291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
    Ząbczyk M; Kopytek M; Natorska J; Undas A
    Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants.
    Sennesael AL; Exner T; Chatelain B; Lessire S; Larock AS; Vancraeynest C; Pochet L; Dogné JM; Spinewine A; Mullier F; Douxfils J
    Thromb Res; 2017 Sep; 157():29-37. PubMed ID: 28686914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple method for removing DOACs from plasma samples.
    Exner T; Michalopoulos N; Pearce J; Xavier R; Ahuja M
    Thromb Res; 2018 Mar; 163():117-122. PubMed ID: 29407622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent.
    Exner T; Favresse J; Lessire S; Douxfils J; Mullier F
    Thromb Res; 2019 Jul; 179():69-72. PubMed ID: 31096112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus-anticoagulant testing at NOAC trough levels.
    Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
    Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
    Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
    Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
    Favaloro EJ; Mohammed S; Curnow J; Pasalic L
    Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.
    Reda S; Brügelmann A; Müller J; Oldenburg J; Pötzsch B; Rühl H
    Sci Rep; 2020 Jul; 10(1):12221. PubMed ID: 32699227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
    Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
    J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury.
    Oberladstätter D; Voelckel W; Schlimp C; Zipperle J; Ziegler B; Grottke O; Schöchl H
    Anaesthesia; 2021 Mar; 76(3):373-380. PubMed ID: 32946123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance Characteristics of DOAC-Remove for Neutralization of the Effects of Apixaban and Rivaroxaban in Lupus Anticoagulant Assays.
    Skaugen JM; Sayre C; Hassett AC; Chibisov I; Bontempo F; Meyer MP; Seheult JN
    Am J Clin Pathol; 2022 Mar; 157(3):457-469. PubMed ID: 34698336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.